Hummingbird Diagnostics is at the forefront of precision medicine, utilizing advanced molecular blood tests that integrate the analysis of tumor and immune system biomarkers. Their innovative approach focuses on interrogating small RNA biomarkers from whole blood, which allows for a comprehensive understanding of both disease states and the host immune response. This methodology is powered by their proprietary mirCator platform, which employs artificial intelligence to enhance the sensitivity and robustness of small RNA analyses. By examining all constituents of blood, Hummingbird Diagnostics aims to provide deep insights that can lead to early disease detection, therapy response prediction, and effective treatment monitoring.

The mirCator platform is designed to streamline the entire operational process, from sample collection to data analysis, ensuring high-quality results through extensive automation and rigorous quality controls. This includes an automated RNA extraction process optimized for small RNAs, which maximizes efficiency while maintaining high yield and integrity. Additionally, Hummingbird Diagnostics has developed a suite of AI-based software solutions that enhance analytic capabilities, minimize data loss, and support versatile biomarker discovery. Their commitment to quality and innovation is further exemplified by the miR-Blood atlas, a comprehensive database that provides insights into small RNA expression in human blood, facilitating a deeper understanding of blood and immune biology.

Germany

Hummingbird extracts deep insights into disease through the integrated analysis of both disease and immune system derived small RNA biomarkers from whole blood.
This dual interrogation of signal from disease and the host response to disease enables a highly sensitive, robust, and AI powered platform that will revolutionize how we diagnose, treat, and manage cancer and other diseases. 

Hummingbird Diagnostics

Company Details